←
ArmandoPérez dePrado4,377 posts
ArmandoPérez dePrado avatar

ArmandoPérez dePrado

@foroic

Interventional cardiologist, science & technology geek. Linked to @foroepic (open discussion forum on interventional cardiology) @fundacionepic @fundepicmedia

◷ Joined October 2010▧ 524 Photos and videos
TCTMD avatar
⟳ ArmandoPérez dePrado retweeted
TCTMD@TCTMD·Nov 13

Guiding DAPT De-escalation With Platelet Function Testing Doesn’t Improve Outcomes: EPIC17-VERONICA bit.ly/4kRsHiB

Post attachment
Fundación EPIC avatar
⟳ ArmandoPérez dePrado retweeted
Fundación EPIC@fundacionepic·Nov 12

Diez años de historias, de personas y de compromiso. ✨ El 28 de enero celebramos la Gala X Aniversario de Fundación EPIC en el Palacete de los Duques de Pastrana. Nos vemos allí. 🤍 #FundaciónEPIC #XAniversario

0:49
C. Michael Gibson MD avatar
⟳ ArmandoPérez dePrado retweeted
C. Michael Gibson MD@CMichaelGibson·Nov 3

Dr. Iñigo Lozano and Dr. C. Michael Gibson discuss the EPIC17-VERONICA trial: De-escalation from potent P2Y12 inhibitors to clopidogrel guided by platelet reactivity testing did not significantly reduce net adverse clinical events at 12 months in ACS patients with low platelet reactivity. Watch video here: clinicaltrialresults.org/wp-…

7:17
C. Michael Gibson MD avatar
⟳ ArmandoPérez dePrado retweeted
C. Michael Gibson MD@CMichaelGibson·Nov 3

EPIC17-VERONICA trial: Platelet reactivity testing to guide P2Y12 inhibitor de-escalation showed a neutral effect on the primary endpoint of net adverse clinical events at 12-month follow-up in ACS patients with very low platelet reactivity, demonstrating no significant reduction in events compared with continuation of potent P2Y12 inhibitors. Download slides here: clinicaltrialresults.org/wp-…

Post attachmentPost attachmentPost attachmentPost attachment
C. Michael Gibson MD avatar
⟳ ArmandoPérez dePrado retweeted
C. Michael Gibson MD@CMichaelGibson·Nov 4

DUOTAP trial: Routine post-dilatation with the original delivery balloon at the identical filling volume achieved a 70% reduction in the transcatheter heart valve asymmetry index at 30 days in patients with severe aortic stenosis undergoing transfemoral transcatheter aortic valve implantation with a balloon-expandable valve, demonstrating optimized transcatheter heart valve geometry and improved expansion. Download slides here: clinicaltrialresults.org/wp-…

Post attachmentPost attachmentPost attachmentPost attachment
C. Michael Gibson MD avatar
⟳ ArmandoPérez dePrado retweeted
C. Michael Gibson MD@CMichaelGibson·Nov 1

Dr. Carlos Collet and Dr. C. Michael Gibson discuss the P4 Trial: Comprehensive CCTA-guided PCI strategy was associated with a lower rate of target vessel failure at 12 months compared to IVUS-guided PCI (4.1% vs. 4.8%) among patients with chronic coronary syndrome or stabilized acute coronary syndrome, supporting procedural safety and non-inferiority. Watch video here: clinicaltrialresults.org/wp-…

9:21